Heat treatment for cold worked nitinol to impart a shape setting capability without eventually developing stress-induced martensite

Information

  • Patent Grant
  • 7976648
  • Patent Number
    7,976,648
  • Date Filed
    Thursday, November 2, 2000
    24 years ago
  • Date Issued
    Tuesday, July 12, 2011
    13 years ago
Abstract
Cold worked nickel-titanium alloys that have linear pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device having a strut formed body deployed from a sheath. In one application, an embolic protection device that employs a linear pseudoelastic nitinol self-expanding strut assembly with a small profile delivery system for use with interventional procedures. The expandable strut assembly is covered with a filter element and both are compressed into a restraining sheath for delivery to a deployment site downstream and distal to an interventional procedure. Once at the desired site, the restraining sheath is retracted to deploy the embolic protection device, which captures flowing emboli generated during the interventional procedure. Linear pseudoelastic nitinol is used in the medical device as distinct from non-linear pseudoelastic (i.e., superelastic) nitinol.
Description
BACKGROUND OF THE INVENTION

The present invention relates generally to application of nickel-titanium alloys to medical devices. More precisely, the present invention is directed to cold worked nickel-titanium alloys that have pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device deployed from a sheath.


Near equi-atomic binary nickel-titanium alloys (nitinol) are known to exhibit “pseudoelastic” behavior when given certain cold working processes or cold working and heat treatment processes following hot working. Generally speaking, “pseudoelasticity” is the capacity of the nickel-titanium alloy to undergo large elastic strains on the order of 8 percent or more when stressed and to substantially fully recover all strain upon removal of the stress. Substantially full recovery is typically understood to be less than 0.5 percent unrecovered strain, also known as permanent set or amnesia.


Pseudoelasticity can be further divided into two subcategories: “linear” pseudoelasticity and “non-linear” pseudoelasticity. “Non-linear” pseudoelasticity is sometimes used by those in the industry synonymously with “superelasticity.”


Linear pseudoelasticity results from cold working only. Non-linear pseudoelasticity results from cold working and subsequent heat treatment. Non-linear pseudoelasticity, in its idealized state, exhibits a relatively flat loading plateau in which a large amount of recoverable strain is possible with very little increase in stress. This flat plateau can be seen in the stress-strain hysteresis curve of the alloy. Linear pseudoelasticity exhibits no such flat plateau. Non-linear pseudoelasticity is known to occur due to a reversible phase transformation from austenite to martensite, the latter more precisely called “stress-induced martensite” (SIM). Linear pseudoelasticity has no such phase transformation associated with it. Further discussions of linear pseudoelasticity can be found in, for example, T. W. Duerig, et al., “Linear superelasticity in Cold-Worked Ni—Ti,” Engineering Aspects of Shape Memory Alloys, pp. 414-19 (1990).


Because of the useful nature of the nickel-titanium alloy, some have attempted to change its properties to solve different design needs. For example, U.S. Pat. No. 6,106,642 to DiCarlo et al. discloses annealing nitinol to achieve improved ductility and other mechanical properties. U.S. Pat. No. 5,876,434 to Flomenblit et al. teaches annealing and deforming nitinol alloy to obtain different stress-strain relationships.


Binary nickel-titanium alloys have been used in the medical field. Many medical device related applications exploit the non-linear pseudoelastic capabilities of nitinol. Examples include: U.S. Pat. Nos. 4,665,906; 5,067,957; 5,190,546; and 5,597,378 to Jervis; and U.S. Pat. Nos. 5,509,923; 5,486,183; 5,632,746; 5,720,754; and 6,004,629 to Middleman, et al.


Yet another application of nickel-titanium alloys is in an embolic protection or filtering device. Such embolic filtering devices and systems are particularly useful when performing balloon angioplasty, stenting procedures, laser angioplasty, or atherectomy in critical vessels, particularly in vessels such as the carotid arteries, where the release of embolic debris into the bloodstream can occlude the flow of oxygenated blood to the brain or other vital organs. Such an occlusion can cause devastating consequences to the patient. While the embolic protection devices and systems are particularly useful in carotid procedures, they are equally useful in conjunction with any vascular interventional procedure in which there is an embolic risk. An embolic protection device that uses superelastic nitinol recently released to the market by the Cordis Corporation is known as the ANGIOGUARD.


What has been needed and heretofore unavailable in the prior art is a medical device that exploits the benefits of linear pseudoelastic nitinol. With the use of linear pseudoelastic nitinol, the mechanical strength of the device is substantially greater per unit strain than a comparable device made of superelastic nitinol. Furthermore, smaller component parts such as struts can be used because of the greater storage of energy available in a linear pseudoelastic nitinol device.


SUMMARY OF THE INVENTION

The present invention is generally directed to cold worked nickel-titanium alloys that have linear pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device having a strut formed body deployed from a sheath.


In one preferred embodiment, the present invention is directed to a medical device for use in a body lumen comprising a body formed from struts, wherein the body includes a cold formed nickel-titanium alloy, and the nickel-titanium alloy is in a martensitic phase when the body is stressed into a first shape and also when the stress to the body is relieved to assume a second shape. The present invention further includes a sheath at least partially enveloping the body in its first shape. The sheath may be used to transport the device to a targeted location in the patient's anatomy, to deploy the device, and to retrieve the device at the end of the procedure.


The raw nitinol for use in the present invention has been cold formed and is further cold worked to set the desired expanded shape. Furthermore, the cold forming and cold working occur below the recrystallization temperature of the nitinol alloy.


During its operation, the linear pseudoelastic nitinol device can be stressed without developing stress-induced martensite in the alloy. Consistent with this behavior, an idealized stress-strain curve of the linear pseudoelastic nitinol does not contain any flat stress plateaus. Furthermore, despite application of stress, the nitinol alloy does not undergo a phase transformation from austenite to martensite or vice versa.


The resulting preferred embodiment device has greater mechanical strength at any given strain as compared to a device made of a standard superelastic nitinol. The stress-strain curve of the present invention linear pseudoelastic nitinol device also possesses more energy storage capacity. As a result, for a given desired performance requirement, the present invention linear pseudoelastic nitinol device allows for smaller struts and consequently a lower profile useful in crossing narrow lesions.


Another advantage is that because the present invention uses linear pseudoelastic nitinol, the underlying alloy can be selected from a broader range of available materials yet still maintain consistent, mechanical properties. In other words, there is less sensitivity to material variations and processing vagaries as compared to superelastic nitinol. In addition, since the linear pseudoelastic nitinol has no transformation from martensite to austenite or vice versa, there is less of an influence by temperature-related effects.


There are many specific applications for the present invention including vena cava filters, septal plugs, just to name a few. One specific application for the present invention is in a filtering device and system for capturing embolic debris in a blood vessel created during the performance of a therapeutic interventional procedure, such as a balloon angioplasty or stenting procedure, in order to prevent the embolic debris from blocking blood vessels downstream from the interventional site. The devices and systems of the present invention are particularly useful while performing an interventional procedure in critical arteries, such as the carotid arteries, in which vital downstream blood vessels can easily become blocked with embolic debris, including the main blood vessels leading to the brain. When used in carotid procedures, the present invention minimizes the potential for a stroke occurring during the procedure. As a result, the present invention provides the physician with a higher degree of confidence that embolic debris is being properly collected and removed from the patient's vasculature during the interventional procedure.


An embolic protection device and system made in accordance with the present invention preferably includes an expandable filter assembly which is affixed to the distal end of a cylindrical shaft, such as a guide wire. The filter assembly includes an expandable strut assembly preferably made from a linear pseudoelastic nitinol, and includes a number of outwardly biased and extending struts that are capable of self-expansion from a contracted or collapsed position to an expanded or deployed position within a patient's vasculature. A filter element made from an embolic capturing media is attached to the expandable strut assembly. The filter element opens from a collapsed configuration to an expanded configuration via the movement of the expandable struts similar to that of an umbrella.


Other features and advantages of the present invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a side elevational view, partially in cross-section, of an embolic protection device embodying features of the present invention showing the expandable filter assembly in its collapsed position within a restraining sheath and disposed within a vessel.



FIG. 2 is a side elevational view, partially in cross-section, similar to that shown in FIG. 1, wherein the expandable filter assembly is in its expanded position within the vessel.



FIG. 3 is a perspective view of an expandable strut assembly which forms part of the filter assembly of the present invention as shown in its collapsed position.



FIG. 4 is a plan view of a flattened section of the expandable strut assembly shown in FIG. 3 which illustrates one particular strut pattern.



FIG. 5 is a set of stress-strain curves for conventional 316L stainless steel, linear pseudoelastic nitinol, and non-linear pseudoelastic nitinol.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is generally directed to cold worked nickel-titanium alloys that have linear'pseudoelastic behavior without a phase transformation or onset of stress-induced martensite as applied to a medical device having a strut formed body deployed from a sheath. Although the present invention is applicable to and contemplates numerous medical devices, for the sake of illustration, the following detail description focuses on an exemplary embodiment involving a filtering device and system for capturing embolic debris in a blood vessel created during the performance of a therapeutic interventional procedure.


In a preferred embodiment, the present invention medical device has a body formed from struts, wherein the body includes a cold formed nickel-titanium alloy, and the nickel-titanium alloy is in a martensitic phase when the body is stressed into a first shape and also when the stress on the body is relieved to assume a second shape. The preferred embodiment further includes a sheath at least partially enveloping the body in its first shape. The sheath may be used to transport the device to a targeted location in the patient's anatomy, to deploy the device, and to retrieve the device at the end of the procedure.


Turning now to the drawings, in which like reference numerals represent like or corresponding elements, FIGS. 1 and 2 illustrate a preferred embodiment embolic protection device 10 incorporating features of the present invention. In the particular exemplary embodiment shown in FIGS. 1 and 2, the embolic protection device 10 has a body identified as a filter assembly 12, which assembly includes an expandable strut assembly 14 and a filter element 16. The filter assembly 12 is rotatably mounted on the distal end of an elongated tubular shaft. The shaft as shown in FIGS. 1 and 2 is a guide wire 18, for example.



FIG. 1 also depicts a delivery system having a small delivery profile P. This reduced profile P is an advantage of the present invention filter assembly 14 and delivery system (restraining sheath 46 and recovery sheath 48), and is a result of the stress-strain hysteresis curve for linear pseudoelastic nitinol. This novel approach is described more fully below.


In the side elevational and cross-sectional views of FIGS. 1 and 2, the embolic protection device 10 is positioned within an artery 20 or other lumen of a patient. This portion of the artery 20 has an area of treatment 22 in which atherosclerotic plaque 24 has built up against the inside wall 26 of the artery 20. The filter assembly 12 is placed distal to, and downstream from, the area of treatment 22.


A balloon angioplasty catheter (not shown) can optionally be introduced within the patient's vasculature in a conventional Seldinger technique through a guiding catheter (not shown). The guide wire 18 is passed through the area of treatment 22 and the dilatation catheter can be advanced over the guide wire 18 within the artery 20 until the balloon portion is appositioned directly in the area of treatment 22. The balloon of the dilatation catheter is inflated, thereby expanding the plaque 24 against the inside wall 26 of the artery 20. This opens the occlusion, expands the artery 20, and reduces the blockage in the vessel caused by the plaque 24.


After the dilatation catheter is removed from the patient's vasculature, a stent 25 (shown in FIG. 2) may be delivered to the area of treatment 22 using over-the-wire techniques. The stent 25 helps to scaffold and maintain the area of treatment 22, which in turn help to prevent restenosis from occurring in the area of treatment 22.


Any embolic debris 27 that breaks off from the plaque 24 during the interventional procedure is released into the bloodstream. The embolic debris 27 is carried by blood flow (indicated by arrows) and is captured by the deployed, i.e., unfurled, filter element 16 of the filter assembly 12 located downstream from the area of treatment 22. Once the interventional procedure is completed, the filter assembly 12 is collapsed and removed from the patient's vasculature, taking with it all embolic debris 27 trapped within the filter element 16.


One exemplary embodiment of the expandable strut assembly 14 is shown in FIGS. 1-2. As can be seen in these figures, the expandable strut assembly 14 includes a plurality of radially expandable struts 28 that can move from a compressed or collapsed position as shown in FIG. 1 to an expanded or deployed position shown in FIG. 2. The expandable strut assembly 14 is preferably made from a linear pseudoelastic nitinol alloy so that the struts 28 have a radially outward bias toward the expanded position.


The expandable strut assembly 14 includes a proximal end 32 which is optionally rotatably attached to the guide wire 18. A distal end 34 is free to slide longitudinally along the guide wire 18 and can rotate thereabout. The distal end 34 translates along the guide wire 18 whenever the struts 28 move between the expanded and contracted positions. A proximal end 32 includes a short tubular segment or sleeve 36 which has a coil spring formed therein and which acts as a dampening member or element 38. The function of the dampening element 38 is explained below. The distal end 34 of the tubing 30 preferably includes a short segment or sleeve 40 which is slidably and rotatably disposed on the guide wire 18.


The filter element 16 in one preferred embodiment of the invention includes a tapered or cone shaped section 50, as seen in FIGS. 1 and 2. The filter element 16 optionally has a plurality of openings 53 that allow the blood to perfuse through (indicated by arrows), yet the openings 53 are small enough that the embolic debris 27 is captured inside the cone shaped section 50. The filter element 16 includes a short proximal section 52 which is integral with the cone shaped section 50 and expands to a substantially cylindrical shape when the struts 28 of strut assembly 14 are deployed. An inlet opening 51 located at the short proximal section 52 of cone shaped section 50 collects embolic debris 27, directing the debris 27 into the filter element 16.


The short proximal section 52 also functions as a superstructure to which the filter element 16 and the struts 28 of the strut assembly 14 can be adhesively or otherwise affixed. At the opposite end, the filter element 16 has a short distal cylindrical section 54 which is integral with the remaining sections of the filter element and is attached to the distal end 34 of the expandable strut assembly 14.


As best seen in FIG. 1, the filter assembly 12 is maintained in its collapsed or compressed position through the use of a restraining sheath 46. The restraining sheath 46 should have sufficient elasticity to resist the outward bias of the struts 28. One manner of achieving the required elasticity is through selection of the proper size and wall thickness for the sheath 46. Another is through use of the proper elastic material that has sufficient resilience to resist the expansive forces of the struts 28 held therein. Such sheath materials and designs are known in the art.


The guide wire 18 and the restraining sheath 46 have proximal ends (not shown) that extend outside of the patient. From outside the patient, it is possible to manipulate the struts 28 into the expanded position by retracting the restraining sheath 46 via its proximal end to expose the struts 28. Since the struts 28 are self-expanding by nature, the withdrawal of the restraining sheath 46 allows the struts 28 to spring open and the filter element 16 to unfurl into their expanded positions within the artery 20. This is depicted in FIG. 2.


The guide wire 18 optionally includes a small sphere 56 affixed thereto. The small sphere 56 is useful during the delivery of the embolic protection device 10 into the patient's vasculature. Specifically, the sphere 56 is approximately as large as the inner diameter of the restraining sheath 46 and is effectively used as a nose cone. The nose cone prevents possible “snowplowing” of the embolic protection device 10 as it is delivered through the patient's arteries.


When the embolic protection device 10 is to be removed from the patient's vasculature, an optional recovery sheath 48 is used to collapse and recover the filter assembly 12, as shown in FIG. 2. Generally, this recovery sheath 48 has a slightly larger inner diameter than the restraining sheath 46 since the struts 28 are now deployed. Furthermore, the recovery sheath 48 must have sufficient tensile strength and elasticity at the distal end 47 to be capable of collapsing the expanded strut assembly 14.


The collapse of the expandable strut assembly 14 can be accomplished by holding the guide wire 18 and moving the proximal end (not shown) of the recovery sheath 48 forward, which moves the distal end 47 of the sheath 48 over the struts 28. Alternatively, the recovery sheath 48 can be held stationary while the proximal end of the guide wire 18 is retracted back to pull the entire filter assembly 12 into the sheath 48. Upon collapse of the filter assembly 12, any embolic debris 27 generated and entering the bloodstream during the interventional procedure remains trapped inside the filter element 16 and is withdrawn from the bloodstream when the embolic protection device 10 is removed from the patient's vasculature.


The number of struts 28 formed on the expandable strut assembly 14 can be any number which provides sufficient expandability within the artery to properly deploy and maintain the filter element 16 in place. In the embodiment shown in FIGS. 1 and 2, the expandable strut assembly has four self-expanding struts 28. Likewise, the particular size and shape of each strut 28 can be varied.



FIGS. 3-4 show an expandable strut assembly 14 having a strut pattern formed from an inverted, triangular shape first portion 60, a substantially straight center section 62, and a second inverted triangular shaped section 64, which completes the strut. This particular strut pattern is one preferred design that provides greater strength in regions of the strut where there would be a tendency for the strut to break or become weakened. These regions include the very proximal and distal ends of each strut which are designed with a wider base. This particular design also allows the expandable strut assembly 14 to open and close more uniformly. This is advantageous especially when collapsing the struts for removal from the patient. Additionally, the center section 62 allows the struts 28 to expand to a greater volume, which allows a larger filter element to be placed on the strut assembly 14, if needed.


When the precise pattern is cut into the tubing 30, a sleeve 36 which forms the proximal end 32 may optionally be formed into a helical coil as shown in FIG. 3. The helical coil then functions as a damping element 38 for the expandable strut assembly 14. As seen in FIGS. 1 and 2, the sleeve 36 slides over the guide wire 18. The proximal end 32 of the expandable strut assembly 14 is mounted between a tapered fitting 42 and an optional radiopaque marker band 44. The tapered end fitting 42 and the marker band 44 affix the proximal end 32 on to the guide wire 18 to prevent any longitudinal motion, yet allow for rotation of the filter assembly 12.



FIG. 4 is a plan view of a rolled out flat sheet of the tubing 30 used to form the struts 28. Preferably, however, the tubing 30 is made from nitinol and the initial state of the tubing is fully martensitic in the as-received condition. A particular design pattern is cut into the thin wall of the tubing 30 in order to form each strut. In the case of the exemplary embodiment shown in FIG. 3, that pattern consists of truncated diamond shape apertures 65 which help form the first section 60, the center section 62 and the triangular shaped section 64. To create the apertures 65, portions of the tubing 30 are selectively removed through laser cutting preferably, but etching, stamping, or other processes are suitable insofar as each particular strut can be fashioned into a precise shape, width, and length. This truncated diamond aperture pattern 65 repeats, as seen in FIG. 4, to provide uniform size to each of the struts 28 formed therein. Narrow struts such as that shown in FIGS. 1 and 2 can, of course, be formed as described above.


Subsequently, the laser cut nitinol tubing 30 is preferably cold formed and specifically cold worked with no heat treatment such that it remains in the fully martensitic state. The cold working proceeds only at temperatures below the recrystallization temperature of the nitinol alloy. Next, the laser-cut nitinol tubing 30 is cold worked to its desired expanded size. The desired expanded size is thus imparted or set into the laser cut tube.


Importantly, the laser-cut nitinol tubing 30 is not heat treated to prevent generation of any loading or unloading plateaus in the stress-strain curve. In an alternative embodiment, the nitinol tubing may undergo heat treating for only very limited durations at low temperatures. The present invention recognizes that a significant difference between linear pseudoelasticity and non-linear pseudoelasticity is the absence or presence, respectively, of stress-induced martensite. It also recognizes that in order to set a particular shape in nitinol, the nitinol must be heat treated at a relatively high temperature for a short period of time. Under normal circumstances, this material would then exhibit non-linear pseudoelasticity and therefore would undergo a reversible phase transformation from austenite to martensite. When setting a shape under standard conditions, for example, 550 degrees C. for 5 minutes, the nitinol exhibits essentially no springback; that is, its unconstrained shape after heat treatment is nearly identical to its constrained shape during heat treatment. The nitinol does not spring back to its original shape prior to heat treatment. At the other extreme, linear pseudoelastic nitinol with no heat treatment has 100 percent springback and always returns to its original, cold worked shape.


Springback is a continuous function between no heat treatment (100 percent springback) and ideal shape setting heat treatment (approximately zero percent springback). From an engineering perspective for design of nitinol based pseudoelastic devices, less springback is more favorable than more springback. However, in some circumstances, linear pseudoelasticity may be preferable to non-linear pseudoelasticity. Therefore, the present invention, in addition to contemplating cold-worked only nitinol, addresses that regime of heat treatment temperatures and times within which springback is adequately minimized to successfully impart a desired shape to the nitinol structure and within which the nitinol does not develop a stable and reversible martensitic phase.


In the preferred embodiment of the present invention, to achieve the linear pseudoelastic behavior, the binary nickel-titanium tubing has approximately 55.8 atomic percent nickel. The tubing must contain a minimum of approximately 38 percent cold working when measured by the reduction in cross-sectional area, and there is not to be any heat treatment following final cold reduction. As to the alternative embodiment, the present invention contemplates accumulated heat treatment of the tubing of up to 300 degrees C. for up to 5 minutes. Under ideal conditions, these process parameters should adequately ensure that the nitinol remains martensitic without a phase change under stress.


To illustrate the foregoing points, FIG. 5 contains the elastic component of three idealized stress-strain curves for 316L stainless steel, linear pseudoelastic nitinol, and non-linear pseudoelastic nitinol. In a preferred embodiment, the expandable strut assembly 14 of the present invention is formed partially or completely of alloys such as the linear pseudoelastic nitinol shown in FIG. 5.


In FIG. 5, in an idealized curve A for a non-linear pseudoelastic nitinol, the relationship is plotted on x-y axes, with the x axis representing strain and the y axis representing stress. The x and y axes are labeled in units of stress from zero to 320 ksi and strain from 0 to 9 percent, respectively.


In curve A, when stress is applied to a specimen of a metal such as nitinol exhibiting non-linear pseudoelastic characteristics at a temperature at or above that which the transformation of the martensitic phase to the austenitic phase is complete, the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced phase transformation from the austenitic phase to the martensitic phase (i.e., the stress-induced martensite phase). As the phase transformation progresses, the alloy undergoes significant increases in strain with little or no corresponding increases in stress. On curve A this is represented by upper, nearly flat stress plateau at approximately 70 to 80 ksi. The strain increases while the stress remains essentially constant until the transformation of the austenitic phase to the martensitic phase is complete. Thereafter, further increase in stress is necessary to cause further deformation. The martensitic metal first yields elastically upon the application of additional stress and then plastically with permanent residual deformation (not shown).


If the load on the specimen is removed before any permanent deformation has occurred, the martensite specimen elastically recovers and transforms back to the austenitic phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the martensitic phase transforms back into the austenitic phase, the stress level in the specimen remains essentially constant (but less than the constant stress level at which the austenitic crystalline structure transforms to the martensitic crystalline structure until the transformation back to the austenitic phase is complete); i.e., there is significant recovery in strain with only negligible corresponding stress reduction. This is represented in curve A by the lower stress plateau at about 20 ksi.


After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as non-linear pseudoelasticity (or superelasticity).



FIG. 5 also has a curve B representing the idealized behavior of linear pseudoelastic nitinol as utilized in the present invention. Curve B generally has a higher slope or Young's Modulus than curve A for the non-linear pseudoelastic nitinol. Also, curve B does not contain any flat plateau stresses found in curve A. This stands to reason since the nitinol of curve B remains in the martensitic phase throughout and does not undergo any phase change. The same tension and release of stress cycle to generate curve A is used to generate curve B. To that end, curve B shows that increasing stress begets a proportional increase in reversible strain, and a release of stress begets a proportional decrease in strain. The areas bounded by curves A and B represent the hysteresis in the nitinol.


As apparent from comparing curve B to curve A in FIG. 5, with the use of linear pseudoelastic nitinol, the mechanical strength of the present invention medical device is substantially greater per unit strain than a comparable device made of superelastic nitinol. Consequently, a major benefit is that smaller component parts such as struts can be used because of the greater storage of energy available in a linear pseudoelastic nitinol device. A small profile is one critical factor for crossing narrow lesions or for accessing remote and tortuous arteries.



FIG. 5 includes curve C which is the elastic behavior of a standard 316L stainless steel. Stress is incrementally applied to the steel and, just prior to the metal deforming plastically, decrementally released. It is provided here simply for comparison to curves A and B.


As mentioned above, the present invention medical device uses preferably a binary nickel-titanium alloy. In an alternative embodiment, however, the nickel-titanium may be alloyed with a ternary element such as palladium, platinum, chromium, iron, cobalt, vanadium, manganese, boron, copper, aluminum, tungsten, tantalum, or zirconium.


While the present invention has been illustrated and described herein in terms of linear pseudoelastic nitinol filter assembly of an embolic protection device and its delivery system, it is apparent to those skilled in the art that the present invention can be used in other instances. Other modifications and improvements may be made without departing from the scope of the present invention.

Claims
  • 1. A method of making an intralumen device, comprising: receiving tubing made from a nickel-titanium alloy that is in a substantially fully martensitic state;forming a plurality of struts in the received tubing to form a body;cold working the body at least about 38 percent as measured by reduction in cross-sectional area, the nickel-titanium alloy remaining in the substantially fully martensitic state following the cold working;heat treating the cold-work body under conditions so that the cold-work body remains in the substantially fully martensitic state; andincorporating the heat-treated cold-worked body into the intralumen device.
  • 2. The method of claim 1 wherein forming a plurality of struts in the received tubing to form a body comprises laser cutting the received tubing to form the plurality of struts.
  • 3. The method of claim 1 wherein forming a plurality of struts in the received tubing to form a body comprises etching the received tubing to form the plurality of struts.
  • 4. The method of claim 1 wherein the nickel-titanium comprises at least one additional alloying element selected from the group consisting of palladium, platinum, tungsten, and tantalum.
  • 5. The method of claim 1 wherein incorporating the heat-treated cold-worked body into the intralumen device comprises incorporating the heat-treated cold-worked body into an embolic filter.
  • 6. A method of making an intralumen device, comprising: receiving tubing made from a nickel-titanium alloy that is in a substantially fully martensitic state;forming a plurality of struts in the received tubing to form a body;cold working the body at least about 38 percent as measured by reduction in cross-sectional area, the nickel-titanium alloy remaining in the substantially fully martensitic state following the cold working;incorporating the cold-worked body into the intralumen device; andwherein an accumulated heat treatment that the received tubing and the cold-worked body receives is up to 300° C. for up to 5 minutes.
  • 7. The method of claim 6 wherein forming a plurality of struts in the received tubing to form a body comprises laser cutting the received tubing to form the plurality of struts.
  • 8. The method of claim 6 wherein forming a plurality of struts in the received tubing to form a body comprises etching the received tubing to form the plurality of struts.
  • 9. The method of claim 6 wherein the nickel-titanium comprises at least one additional alloying element selected from the group consisting of palladium, platinum, tungsten, and tantalum.
  • 10. The method of claim 6 wherein incorporating the cold-worked body into the intralumen device comprises incorporating the cold-worked body into an embolic filter.
US Referenced Citations (285)
Number Name Date Kind
2738294 Spence Mar 1956 A
2768271 Meredith Oct 1956 A
3558369 Wang et al. Jan 1971 A
3605725 Bentov Sep 1971 A
3620212 Fannon et al. Nov 1971 A
3753700 Harrison et al. Aug 1973 A
3890977 Wilson Jun 1975 A
3953253 Clark Apr 1976 A
4019899 Negishi et al. Apr 1977 A
4037324 Andreasen Jul 1977 A
4069226 Kablaoui et al. Jan 1978 A
4144057 Melton et al. Mar 1979 A
4233690 Akins Nov 1980 A
4283233 Goldstein et al. Aug 1981 A
4304613 Wang et al. Dec 1981 A
4310354 Fountain et al. Jan 1982 A
4323071 Simpson et al. Apr 1982 A
4386971 Melton et al. Jun 1983 A
4390599 Broyles Jun 1983 A
4411655 Schreck Oct 1983 A
4425908 Simon Jan 1984 A
4427000 Ueda Jan 1984 A
4439185 Lundquist Mar 1984 A
4503569 Dotter Mar 1985 A
4505767 Quin Mar 1985 A
4512338 Balko et al. Apr 1985 A
4516972 Samson May 1985 A
4518444 Albrecht et al. May 1985 A
4533411 Melton Aug 1985 A
4538622 Samson et al. Sep 1985 A
4554929 Samson et al. Nov 1985 A
4565589 Harrison Jan 1986 A
4580568 Gianturco Apr 1986 A
4582181 Samson Apr 1986 A
4616652 Simpson Oct 1986 A
4631094 Simpson et al. Dec 1986 A
4638805 Powell Jan 1987 A
4665906 Jervis May 1987 A
4740253 Simpson et al. Apr 1988 A
4748986 Morrison et al. Jun 1988 A
4768507 Fischell et al. Sep 1988 A
4770725 Simpson et al. Sep 1988 A
4776844 Ueda Oct 1988 A
4793350 Mar et al. Dec 1988 A
4827941 Taylor et al. May 1989 A
4846573 Taylor et al. Jul 1989 A
4856516 Hillstead Aug 1989 A
4865663 Tuominen et al. Sep 1989 A
4875489 Messner et al. Oct 1989 A
4881981 Thoma et al. Nov 1989 A
4894100 Yamauchi et al. Jan 1990 A
4925445 Sakamoto et al. May 1990 A
4935068 Duerig Jun 1990 A
4943326 Ozawa et al. Jul 1990 A
4969890 Sugita et al. Nov 1990 A
4984581 Stice Jan 1991 A
4991602 Amplatz et al. Feb 1991 A
5001446 Tsuji et al. Mar 1991 A
5002563 Pyka et al. Mar 1991 A
5025799 Wilson Jun 1991 A
5044947 Sachdeva et al. Sep 1991 A
5067489 Lind Nov 1991 A
5067957 Jervis Nov 1991 A
5069226 Yamauchi et al. Dec 1991 A
5092877 Pinchuk Mar 1992 A
5108523 Peterseim et al. Apr 1992 A
5114504 AbuJudom, II et al. May 1992 A
5117838 Palmer et al. Jun 1992 A
5120308 Hess Jun 1992 A
5135503 Abrams Aug 1992 A
5143085 Wilson Sep 1992 A
5171383 Sagaye et al. Dec 1992 A
5188621 Samson Feb 1993 A
5190546 Jervis Mar 1993 A
5201901 Harada et al. Apr 1993 A
5230348 Ishibe et al. Jul 1993 A
5230349 Langberg Jul 1993 A
5234458 Metais Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5243996 Hall Sep 1993 A
5271975 Solano Dec 1993 A
5292331 Boneau Mar 1994 A
5318527 Hyde et al. Jun 1994 A
5341815 Cofone et al. Aug 1994 A
5341818 Abrams et al. Aug 1994 A
5345937 Middleman et al. Sep 1994 A
5345945 Hodgson et al. Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5350419 Bendel et al. Sep 1994 A
5354623 Hall Oct 1994 A
5368049 Raman et al. Nov 1994 A
5411476 Abrams et al. May 1995 A
5458615 Klemm et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5486183 Middleman et al. Jan 1996 A
5507766 Kugo et al. Apr 1996 A
5509923 Middleman et al. Apr 1996 A
5514154 Lau et al. May 1996 A
5534007 St. Germain et al. Jul 1996 A
5549626 Miller et al. Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5569295 Lam Oct 1996 A
5573520 Schwartz et al. Nov 1996 A
5597378 Jervis Jan 1997 A
5607444 Lam Mar 1997 A
5611874 Zadno-Azizi et al. Mar 1997 A
5630840 Mayer May 1997 A
5632746 Middleman et al. May 1997 A
5637089 Abrams et al. Jun 1997 A
5641364 Goldberg et al. Jun 1997 A
5643312 Fischell et al. Jul 1997 A
5667522 Flomenblit et al. Sep 1997 A
5690644 Yurek et al. Nov 1997 A
5695111 Nanis et al. Dec 1997 A
5713853 Clark et al. Feb 1998 A
5720300 Fagan et al. Feb 1998 A
5720754 Middleman et al. Feb 1998 A
5749370 Brooks et al. May 1998 A
5749870 Gloth et al. May 1998 A
5749879 Middleman et al. May 1998 A
5759192 Saunders Jun 1998 A
5766218 Arnott Jun 1998 A
5776114 Frantzen et al. Jul 1998 A
5780807 Saunders Jul 1998 A
5810874 Lefebvre Sep 1998 A
5820628 Middleman et al. Oct 1998 A
5833631 Nguyen Nov 1998 A
5836966 St. Germain Nov 1998 A
5836968 Simon et al. Nov 1998 A
5837313 Ding et al. Nov 1998 A
5843244 Pelton et al. Dec 1998 A
5865768 Orr Feb 1999 A
5876356 Viera et al. Mar 1999 A
5876434 Flomenblit et al. Mar 1999 A
5885381 Mitose et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5902317 Kleshinski et al. May 1999 A
5904690 Middleman et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5922393 Jayaraman Jul 1999 A
5927345 Samson Jul 1999 A
5931819 Fariabi Aug 1999 A
5951793 Mitose et al. Sep 1999 A
5964770 Flomenblit et al. Oct 1999 A
5976153 Fischell et al. Nov 1999 A
5980471 Jafari Nov 1999 A
5980566 Alt et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
6001123 Lau Dec 1999 A
6004330 Middleman et al. Dec 1999 A
6004629 Madigan Dec 1999 A
6007558 Ravenscroft et al. Dec 1999 A
RE36628 Sagae et al. Mar 2000 E
6051021 Frid Apr 2000 A
6053992 Wu et al. Apr 2000 A
6059738 Stoltze et al. May 2000 A
6059810 Brown et al. May 2000 A
6066149 Samson et al. May 2000 A
6068610 Ellis et al. May 2000 A
6068623 Zadno-Azizi et al. May 2000 A
6077287 Taylor et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6086610 Duerig et al. Jul 2000 A
6096175 Roth Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6106642 DiCarlo et al. Aug 2000 A
6129739 Khosravi Oct 2000 A
6131266 Saunders Oct 2000 A
6137060 Avellanet Oct 2000 A
6152946 Broome et al. Nov 2000 A
6165140 Ferrera Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6165292 Abrams et al. Dec 2000 A
6168571 Solar et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171334 Cox Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6183409 Armini Feb 2001 B1
6190332 Muni et al. Feb 2001 B1
6210312 Nagy Apr 2001 B1
6217567 Zadno-Azizi et al. Apr 2001 B1
6217589 McAlister Apr 2001 B1
6245103 Stinson Jun 2001 B1
6257513 Cockerham et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6277139 Levinson et al. Aug 2001 B1
6280539 Abrams et al. Aug 2001 B1
6287336 Globerman et al. Sep 2001 B1
6306141 Jervis Oct 2001 B1
6312454 Stöckel et al. Nov 2001 B1
6312455 Duerig et al. Nov 2001 B2
6322847 Zhong et al. Nov 2001 B1
6325824 Limon Dec 2001 B2
6329069 Azizi et al. Dec 2001 B1
6346116 Brooks et al. Feb 2002 B1
6352515 Anderson et al. Mar 2002 B1
6358556 Ding et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6375458 Moorleghem et al. Apr 2002 B1
6375628 Zadno-Azizi et al. Apr 2002 B1
6375629 Muni et al. Apr 2002 B1
6379369 Abrams et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6390993 Cornish et al. May 2002 B1
6391502 Anderson et al. May 2002 B1
6402761 McAlister Jun 2002 B2
6419692 Yang et al. Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428634 Besselink et al. Aug 2002 B1
6432116 Callister et al. Aug 2002 B1
6447523 Middleman et al. Sep 2002 B1
6451047 McCrea et al. Sep 2002 B2
6451052 Burmeister et al. Sep 2002 B1
6458145 Ravenscroft et al. Oct 2002 B1
6461453 Abrams et al. Oct 2002 B1
6468230 Muni et al. Oct 2002 B2
6500182 Foster Dec 2002 B2
6508803 Horikawa et al. Jan 2003 B1
6509094 Shah et al. Jan 2003 B1
6533805 Jervis Mar 2003 B1
6554848 Boylan et al. Apr 2003 B2
6558405 McInnes May 2003 B1
6572646 Boylan et al. Jun 2003 B1
6582461 Burmeister et al. Jun 2003 B1
6592559 Pakter et al. Jul 2003 B1
6592570 Abrams et al. Jul 2003 B2
6602208 Jafari Aug 2003 B2
6602228 Nanis et al. Aug 2003 B2
6602272 Boylan et al. Aug 2003 B2
6626937 Cox Sep 2003 B1
6638372 Abrams Oct 2003 B1
6682608 Abrams et al. Jan 2004 B2
6706053 Boylan et al. Mar 2004 B1
6755855 Yurek et al. Jun 2004 B2
6824560 Pelton Nov 2004 B2
6830638 Boylan et al. Dec 2004 B2
6855161 Boylan et al. Feb 2005 B2
7037320 Brady May 2006 B2
7128757 Boylan et al. Oct 2006 B2
7244319 Abrams et al. Jul 2007 B2
7258753 Abrams et al. Aug 2007 B2
20010007953 Duerig et al. Jul 2001 A1
20010039446 Edwin et al. Nov 2001 A1
20010039449 Johnson et al. Nov 2001 A1
20010047202 Slaikeu et al. Nov 2001 A1
20010049549 Boylan et al. Dec 2001 A1
20020010481 Jayaraman et al. Jan 2002 A1
20020046785 Abrams et al. Apr 2002 A1
20020052627 Boylan et al. May 2002 A1
20020062092 Muni et al. May 2002 A1
20020068954 Foster Jun 2002 A1
20020082681 Boylan et al. Jun 2002 A1
20020087099 Nanis et al. Jul 2002 A1
20020121316 Abrams et al. Sep 2002 A1
20020138129 Armstrong et al. Sep 2002 A1
20020193824 Boylan et al. Dec 2002 A1
20020193827 McGuckin, Jr. et al. Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030036794 Ragheb et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030055449 Lee et al. Mar 2003 A1
20030055484 Lau et al. Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069521 Reynolds et al. Apr 2003 A1
20030120181 Toma et al. Jun 2003 A1
20030127158 Abrams et al. Jul 2003 A1
20030158575 Boylan et al. Aug 2003 A1
20030199920 Boylan et al. Oct 2003 A1
20040084115 Abrams et al. May 2004 A1
20040093009 Denison et al. May 2004 A1
20040158281 Boylan et al. Aug 2004 A1
20040172055 Huter et al. Sep 2004 A1
20040220608 D'Aquanni et al. Nov 2004 A1
20050038500 Boylan et al. Feb 2005 A1
20060086440 Boylan et al. Apr 2006 A1
20060212068 Boylan Sep 2006 A1
20070233179 Brady et al. Oct 2007 A1
20070239259 Boylan Oct 2007 A1
20070249965 Abrams et al. Oct 2007 A1
20080027532 Boylan et al. Jan 2008 A1
20090098013 Boylan et al. Apr 2009 A1
20090248130 Boylan Oct 2009 A1
20100125329 Lin et al. May 2010 A1
Foreign Referenced Citations (84)
Number Date Country
0145166 Jun 1985 EP
0199715 Oct 1986 EP
0340304 Nov 1989 EP
0395098 Oct 1990 EP
0480427 Apr 1992 EP
0484805 May 1992 EP
0491349 Jun 1992 EP
0515078 Nov 1992 EP
0520073 Dec 1992 EP
0550258 Jul 1993 EP
0550288 Jul 1993 EP
0569166 Nov 1993 EP
0791340 Aug 1997 EP
0804934 Nov 1997 EP
0806220 Nov 1997 EP
0812928 Dec 1997 EP
0815803 Jan 1998 EP
0 873 734 Oct 1998 EP
0879614 Nov 1998 EP
0968688 Jan 2000 EP
1027906 Aug 2000 EP
1426071 Jun 2004 EP
44-31704 Dec 1969 JP
44-32286 Dec 1969 JP
53-12759 Feb 1978 JP
55-164304 Dec 1980 JP
57-89859 Jun 1982 JP
58-161746 Sep 1983 JP
60-145155 Jul 1985 JP
60-138547 Sep 1985 JP
60-248856 Dec 1985 JP
61-84361 Apr 1986 JP
61-183455 Aug 1986 JP
62-199757 Sep 1987 JP
62-199758 Sep 1987 JP
62-235449 Oct 1987 JP
63-171570 Jul 1988 JP
64-49571 Feb 1989 JP
1-124473 May 1989 JP
1-242763 Sep 1989 JP
2252467 Oct 1990 JP
2289265 Nov 1990 JP
2289266 Nov 1990 JP
4-9162 Jan 1992 JP
50-19512 Jan 1993 JP
5-092044 Apr 1993 JP
6-83726 Mar 1994 JP
61-08431 Apr 1994 JP
09-215753 Aug 1997 JP
11-76420 Mar 1999 JP
2000-140124 May 2000 JP
03-295562 Oct 2003 JP
4-292174 Oct 2004 JP
WO 8910088 Nov 1989 WO
WO 8912175 Dec 1989 WO
WO 9013329 Nov 1990 WO
WO 9115152 Oct 1991 WO
WO 9205828 Apr 1992 WO
WO 9319803 Oct 1993 WO
WO 9519800 Jul 1995 WO
WO 9724978 Jul 1997 WO
WO 9738747 Oct 1997 WO
WO 9820801 May 1998 WO
WO 9820810 May 1998 WO
WO 9932051 Jul 1999 WO
WO 9944542 Sep 1999 WO
WO 0004846 Feb 2000 WO
WO 0049970 Aug 2000 WO
WO 0067665 Nov 2000 WO
WO 0067668 Nov 2000 WO
WO 0069359 Nov 2000 WO
WO 0139695 Jun 2001 WO
WO 0141859 Jun 2001 WO
WO 0182830 Nov 2001 WO
WO 0236841 May 2002 WO
WO 02051462 Jul 2002 WO
WO 02102281 Dec 2002 WO
WO 03002166 Jan 2003 WO
WO 03028796 Apr 2003 WO
WO 03097148 Nov 2003 WO
WO 2004033016 Apr 2004 WO
WO 2004098458 Nov 2004 WO
WO 2005102407 Nov 2005 WO
WO 2006081011 Aug 2006 WO